1-3 of 3 results for subject:"PTC Therapeutics"
Librarians' tools
- Search time
- 0.172 seconds
- Solr query time
- 0.001 seconds
- Search query
- subject:"PTC Therapeutics"
- We searched for
- subject_t:"PTC Therapeutics" OR subject_ses:426902
Type
House
Session
Year
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health and Social Care, if he will list all signatories to the managed access agreement between NHS England and PTC Therapeutics for the drug Translarna.
To ask the Secretary of State for Health and Social Care, if he will list all signatories to the managed access agreement between NHS England and PTC Therapeutics for the drug Translarna.
The Managed Access Agreement relating to Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy, including a list of signatories, is available at the following link:
To ask the Secretary of State for Health, pursuant to the Answer of 25 May 2016 to Question 37646, what preparatory work NHS England is undertaking on Translarna; and whether a date has been set for a commercial meeting between NHS England and PTC Therapeutics after that preparatory work.
To ask the Secretary of State for Health, pursuant to the Answer of 25 May 2016 to Question 37646, what preparatory work NHS England is undertaking on Translarna; and whether a date has been set for a commercial meeting between NHS England and PTC Therapeutics after that preparatory work.
Further to the answer given in Question 37646, NHS England has been undertaking the detailed preparatory work required to meet the National Institute of Health and Care Excellence’s request that NHS England and the supplier, PTC Therapeutics, work towards agreeing an acceptable managed access arrangement for Translarna (ataluren) by 7 July 2016.
NHS England will be meeting with the supplier when it has concluded this preparatory work. There have not been any commercial meetings with PTC Therapeutics in the period since 15th April 2016 - however, NHS England is in regular contact with the supplier and will be agreeing mutually convenient times to meet.
To ask the Secretary of State for Health, how many meetings NHS England has had with PTC Therapeutics to discuss an agreement on price for Translarna to treat Duchenne muscular dystrophy since 15 April 2016.
To ask the Secretary of State for Health, how many meetings NHS England has had with PTC Therapeutics to discuss an agreement on price for Translarna to treat Duchenne muscular dystrophy since 15 April 2016.
NHS England has advised that on 4 May 2016 the National Institute for Health and Care Excellence (NICE) asked NHS England and PTC Therapeutics to continue to work towards agreeing an acceptable managed access arrangement for Translarna (ataluren) for the treatment of children aged five and over with Duchenne muscular dystrophy caused by a nonsense mutation.
NHS England and the company have been asked to reach agreement on the cost of the drug to the National Health Service by 7 July.
NHS England has advised there have not been any commercial meetings with PTC Therapeutics in the period since 15 April 2016, however, it is in regular contact with the company.
NHS England will be meeting with PTC Therapeutics when it has concluded the detailed preparatory work required to effectively respond to NICE's request within the set timescale.